Literature DB >> 6281516

Receptor-mediated low-density lipoprotein catabolism.

F A Spengel, G R Thompson.   

Abstract

Low-density lipoprotein (LDL) receptors are demonstrable in cultured fibroblasts from normal subjects but are decreased or absent in cells from patients with heterozygous or homozygous familial hypercholesterolaemia. In vivo receptor-mediated LDL catabolism, determined as the difference between the turnover rates of 125I-LDL and 131I-LDL coupled with cyclohexanedione, is responsible for approximately one-third of the total catabolism of LDL in normal subjects, but less than one-fifth in heterozygotes and is totally absent in homozygotes. Receptor-mediated catabolism can be stimulated in normal subjects and in heterozygotes by measures that promote bile acid synthesis, namely, administration of anion-exchange resins or creating a partial ileal bypass. Studies in dogs have shown that such measures stimulate the high-affinity binding of LDL by liver cell membranes. Taken together, these observations suggest the existence of LDL receptors in human liver, the function of which is to maintain cholesterol homeostasis within the hepatocyte during periods of increased demand. Partial or complete absence of such hepatic receptors may play a major role in the pathogenesis of familial hypercholesterolaemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281516     DOI: 10.1007/bf01721621

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  32 in total

1.  Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex.

Authors:  M S Brown; P T Kovanen; J L Goldstein
Journal:  Recent Prog Horm Res       Date:  1979

2.  Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol.

Authors:  P T Kovanen; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1979-11-25       Impact factor: 5.157

3.  Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.

Authors:  E Hirvonen; M Mälkönen; V Manninen
Journal:  N Engl J Med       Date:  1981-03-05       Impact factor: 91.245

4.  Control of sterol synthesis and of hydroxymethylglutaryl CoA reductase in skin fibroblasts grown from patients with homozygous type II hyperlipoproteinemia.

Authors:  J Avigan; S J Bhathena; M E Schreiner
Journal:  J Lipid Res       Date:  1975-03       Impact factor: 5.922

5.  Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor.

Authors:  J L Goldstein; S E Dana; G Y Brunschede; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

6.  Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts.

Authors:  T P Bersot; R W Mahley; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1976-04-25       Impact factor: 5.157

7.  Serum cholesterol levels in patients with familial hypercholesterolemia confirmed by tissue culture.

Authors:  C Keller; K Harders-Spengel; F Spengel; A Wieczorek; G Wolfram; N Zöllner
Journal:  Atherosclerosis       Date:  1981-04       Impact factor: 5.162

8.  Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases.

Authors:  V Beaumont; B Jacotot; J L Beaumont
Journal:  Atherosclerosis       Date:  1976-09       Impact factor: 5.162

9.  Localization of low density lipoprotein receptors on plasma membrane of normal human fibroblasts and their absence in cells from a familial hypercholesterolemia homozygote.

Authors:  R G Anderson; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

10.  The effect of cholestyramine on the faecal excretion of bile acids and neutral steroids in familial hypercholesterolaemia.

Authors:  C D Moutafis; L A Simons; N B Myant; P W Adams; V Wynn
Journal:  Atherosclerosis       Date:  1977-03       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.